Journal

Archives of Razi Institute

Papers (2)

Anti-proliferative Activity of Vitex negundo Leaf Extracts on PA1 Human Ovarian Cancer Cell Lines

In Ayurveda, Vitex negundo (VN) is used as a drug to manage pain, inflammation, problems related to polycystic ovary disease and the menstrual cycle. The bioactive compounds isolated from this plant exhibit anti-inflammatory, anti-oxidant, anti-cancer and microbicidal properties. The shrub Vitex negundo is known for its role in the modulation of cellular events like apoptosis and cell cycle. There is still a scarcity of data in the literature on the cytotoxic activity of Vitex negundo extracts on ovarian cancer. Hence, in this study, the phytochemical composition, anti-oxidant and anti-cancer activities of leaf extracts were evaluated. The chloroform and methanol fractions exhibited higher phenolic content (161.04 ± 0.02 mg/g GAE and 152.56 ± 0.05 mg/g GAE respectively) as compared to other fractions. The aqueous and petroleum ether fractions exhibited higher flavonoid content (515.27 ± 0.28 mg/g QE and 211.82 ± 0.05 mg/g QE respectively). The acetone and methanol extracts showed significant anti-oxidant capacities. Both leaf extracts of Vitex negundo inhibited PA1 cancer cell growth in a dose-dependent manner with IC50 values of 88.01 ± 3.14 and 112.30 ± 1.93 μg/ml respectively, as compared to the standard drug Doxorubicin with IC50 value 2.91 μg/ml (p < 0.05, One - Way ANOVA). The Gas Chromatography - Mass Spectroscopy (GC-MS) analysis allowed us to identify twenty- five bioactive compounds in acetone extract and twenty- two compounds in methanol extract. Therefore, further studies should focus on the isolation of novel compounds, which are more effective and less toxic, and constitute interesting substitutes for the development of anti-cancer drugs.

Bcl-2 May Contribute to Evolution of Endometrial Hyperplasia, but It Isn’t a Factor in Subsequent Carcinogenesis

Endometrial carcinoma is common in the western world and is increasing in frequency in developing countries as well. Endometrial hyperplasia is considered to be a precancerous lesion. Apoptosis plays an important role in the neoplastic transformation of cells, with Bcl-2 being an anti-apoptotic cellular marker. Bcl-2 may have an important contribution to the development of endometrial carcinoma. The aim was to evaluate and compare the expression of markers Bcl-2 through the spectrum of normal endometrium, endometrial hyperplasias and endometrial adenocarcinomas. 50 cases were included in this study, comprising of 10 cases of normal endometrium, 10 cases of endometrial hyperplasia without atypia, 10 cases of atypical endometrial hyperplasia and 20 cases of endometrial adenocarcinomas from January 2017 to June 2018. Immunohistochemical staining with Bcl-2 was performed and the results were analyzed. Bcl-2 staining showed an increase in cases with strong intensity of staining from normal endometrium (20% cases) to cases of endometrial hyperplasia (75% cases). There was, however a decrease in the number of cases with strong intensity Bcl-2 staining as the lesions progressed from endometrial hyperplasia to endometrial carcinoma (30% cases). The results were statistically significant (P =0.00309). However, there was no significant association of staining between atypical hyperplasia and endometrial carcinomas (p=0.429), as well as the degree of carcinoma (p=0.6903). Bcl-2 expression showed an increase from cases of normal endometrium to endometrial hyperplasia supporting the process of increased anti- apoptotic activity in endometrial hyperplastic lesions. Its decreased expression in endometrioid adenocarcinoma when compared to endometrial hyperplasias could point towards other mechanisms of carcinogenesis other than failure of apoptosis.

Publisher

DoNotEdit

ISSN

2008-9872